Gossamer Bio announces up to $250M private placement for seralutinib
Gossamer Bio says it has entered a structured private placement for up to $250M, including $150M of committed capital, to fund seralutinib through potential FDA approval and operations into 2028.
GOSS Gossamer Bio announces up to $250M structured private placement, including $150M of committed capital, to fund seralutinib through potential FDA approval Gossamer Bio, - proceeds expected to fund operations into 2028 - $25M funded at initial closing, $125M upon FDA NDA Acceptance - Up to $100M additional funding upon FDA approval of seralutinib